1. Ex-FDA Chief Gottlieb says regulator needs to up pace on COVID-19 drugs— Gilead won't be charging for use of experimental COVID drug, for now — FDA backs first emergency COVID-19 antibody test from Cellex — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Acthar pulmonary studies

Discussion in 'Mallinckrodt' started by anonymous, Sep 11, 2019 at 12:21 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This is absolutely correct. There is a big reorg about to occur. It’s going to be a bloodbath especially on the field side. Marketing there aren’t a lot people left, but the reorg will eliminate a lot of the dead weight. Top ARD performers / high volume areas will be kept. They are talking about “ lean and efficient” sales force. If you are retained, don’t stay comfortable. Due to the payer Acthar landscape, the end is near. DO NOT STAY COMFORTABLE, COMPLACENT OR NAIVE; PLEASE LOOK OUT FOR YOU AND YOUR FAMILY!!!!!!!
     

  2. anonymous

    anonymous Guest

    Hard to believe that people here have to be warned.

    No jobs at this company are safe. Go fined another place to work already.
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    Why are you still here, your all toast. Get out
     
  5. anonymous

    anonymous Guest

    Never. Hugh said a year ago the stock will go up. I have it on tape. And there are 8 recordings of MT saying payers are ready to make deals with us. I put my life savings into this stock based off what those two promised.
     
  6. anonymous

    anonymous Guest

    Why would you put your life savings behind the words of two well known liars and scammers??
     
  7. anonymous

    anonymous Guest

    Did you know the word “gullible” isn’t in the dictionary?
     
  8. anonymous

    anonymous Guest

    Says you. They stood in front of analysts and the company. They said it was under valued. They said payers were talking. This stock is coming back. Hugh said and he’s super smart. The board told him. This stock will be$30 before years end. Thanks Mark and Hugh for being there for us
     
  9. anonymous

    anonymous Guest

    Hahahahaha! Thanks Marky Mark and Hughey for your post! You are great comedians!
     
  10. anonymous

    anonymous Guest

    Ok, John boy.
     
  11. anonymous

    anonymous Guest

    Pulm team for sure. Chatty Kathy’s all fukin day. That will all end soon. That lazy town is over.
     
  12. anonymous

    anonymous Guest

    EXACTLY, lazy town! Why not get rid of pulm altogether and let rhem pick that up like we did before pulm ever started. Their sales are in the tank anyway. Waste of $ that could support more profitable divisions.
     
  13. anonymous

    anonymous Guest

    Totally agree. Pulm is dead. They chat all day, loudly!!!!!!, waste money. That Pulm team can go. Marketing and sales. Waste of fukin money. All of them.
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

    Pulm has real data!
     
  16. anonymous

    anonymous Guest

    Ophthalmology. Thoughts on future????
     
  17. anonymous

    anonymous Guest

    Lol. Ok. Keep thinking that. That stellar team will pull it thru. They look really busy
     
  18. anonymous

    anonymous Guest

    if you are asking you know the answer.
     
  19. anonymous

    anonymous Guest

     
  20. anonymous

    anonymous Guest